Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Registered Randomized, Double-Blind, Placebo-Controlled (2:1), Multi-Centered Clinical Trial of Anlotinib as a Treatment for Advanced Non-Small Cell Lung Cancer

Next Previous
Trial Profile

A Registered Randomized, Double-Blind, Placebo-Controlled (2:1), Multi-Centered Clinical Trial of Anlotinib as a Treatment for Advanced Non-Small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Catequentinib (Primary)
  • Indications Adenocarcinoma; Liver metastases; Non-small cell lung cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ALTER0303
  • Sponsors Chia Tai Tianqing Pharmaceutical Group

    • Most Recent Events

    • 01 Apr 2023 Results of post hoc analysis (n=437) assessing the effects and prognosis in non-small cell lung cancer patients with liver metastasis patients treated with anlotinib, published in the Journal of Cancer Research and Clinical Oncology.
    • 14 Sep 2021 Results of this post-hoc analysis assessing the effect and safety of Anlotinib as a third line or further therapy in non-small cell lung cancer patients with liver metastasis presented at the 2021 World Conference on Lung Cancer
    • 20 May 2020 Results assessing cost-effectiveness of anlotinib as the third-line and further therapy from the Chinese payer perspective using data from this trial, presented at the 25th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top